Endostatin: A novel inhibitor of androgen receptor function in prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 5, 2015, Pages 1392-1397

  Lee, Joo Hyoung ^a   Isayeva, Tatyana ^a   Larson, Matthew R ^a   Sawant, Anandi ^a   Cha, Ha Ram ^a   Chanda, Diptiman ^a   Chesnokov, Igor N ^b   Ponnazhagan, Selvarangan ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor; Chemoresistance; Endostatin; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ENDOSTATIN; PHENYLALANINE; ANTIANDROGEN;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; BINDING SITE; CELL NUCLEUS; MALE; METABOLISM; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; BINDING SITES; CELL NUCLEUS; ENDOSTATINS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84922309424     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1417660112     Document Type: Article

References (36)

1. Korpal M, et al. (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Disc 3(9):1030-1043.
2. Shafi AA, Yen AE, Weigel NL (2013) Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 140(3):223-238.
3. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS (2014) Targeting the androgen receptor pathway in castration-resistant prostate cancer: Progresses and prospects. Oncogene, 10.1038/onc.2014.115.
4. Yuan X, Balk SP (2009) Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27(1):36-41.
5. Chen CD, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33-39.
6. Joseph JD, et al. (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Disc 3(9):1020-1029.
7. Marneros AG, Olsen BR (2005) Physiological role of collagen XVIII and endostatin. FASEB J 19(7):716-728.
8. O'Reilly MS, et al. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277-285.
9. Skovseth DK, Veuger MJ, Sorensen DR, De Angelis PM, Haraldsen G (2005) Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 105(3):1044-1051.
10. Thomas JP, et al. (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21(2):223-231.
11. Fu Y, Tang H, Huang Y, Song N, Luo Y (2009) Unraveling the mysteries of endostatin. IUBMB Life 61(6):613-626.
12. Kisker O, et al. (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61(20):7669-7674.
13. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 97(9):4802-4807.
14. Abdollahi A, et al. (2007) Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 104(31):12890-12895.
15. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67(12):5789-5797.
16. Chang C, Lee SO, Yeh S, Chang TM (2014) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 33(25):3225-3234.
17. He B, et al. (2004) Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16(3):425-438.
18. He B, Wilson EM (2002) The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab 75(4):293-298.
19. Bai S, He B, Wilson EM (2005) Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 25(4):1238-1257.
20. Hur E, et al. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2(9):E274.
21. He B, Wilson EM (2003) Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol 23(6):2135-2150.
22. Hohenester E, Sasaki T, Olsen BR, Timpl R (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 17(6):1656-1664.
23. Ding YH, et al. (1998) Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci USA 95(18):10443-10448.
24. Chura-Chambi RM, Genova LA, Affonso R, Morganti L (2008) Refolding of endostatin from inclusion bodies using high hydrostatic pressure. Anal Biochem 379(1):32-39.
25. Huang X, et al. (2001) Soluble recombinant endostatin purified from Escherichia coli: Antiangiogenic activity and antitumor effect. Cancer Res 61(2):478-481.
26. Dhanabal M, et al. (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274(17):11721-11726.
27. Wickström SA, Alitalo K, Keski-Oja J (2002) Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62(19):5580-5589.
28. Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S (2009) Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. Prostate 69(10):1055-1066.
29. Lee DK, Chang C (2003) Endocrine mechanisms of disease: Expression and degradation of androgen receptor: Mechanism and clinical implication. J Clin Endocrinol Metab 88(9):4043-4054.
30. Balbas MD, et al. (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2:e00499.
31. Li B, Wu X, Zhou H, Chen Q, Luo Y (2004) Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry 43(9):2550-2557.
32. Zhou H, Wang W, Luo Y (2005) Contributions of disulfide bonds in a nested pattern to the structure, stability, and biological functions of endostatin. J Biol Chem 280(12): 11303-11312.
33. Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Jänne OA (2010) Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317(1-2):14-24.
34. Recchia AG, et al. (2009) A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol 41(3): 603-614.
35. Arora VK, et al. (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309-1322.
36. Centenera MM, Harris JM, Tilley WD, Butler LM (2008) The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol 22(11):2373-2382.